CGC, CA1380357048

Canopy Growth stock carries Zacks Rank #4 after estimate cuts

Published on 11/17/2026 at 22:50 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Canopy Growth stock carries a Zacks Rank #4 (Sell) after sharp cuts to the current-year earnings consensus. The latest quarter showed revenue growth but a wider loss.

Analyst downgrade and estimate revisions

  • Zacks Equity Research reported a Zacks Rank #4 (Sell) for Canopy Growth on November 12.
  • The current fiscal-year earnings consensus fell 66.7% over the previous 30 days, according to Zacks.
  • Canopy Growth reported 22% second-quarter revenue growth on November 6, while its net loss widened because of fair-value charges.
CGC, CA1380357048, Illustration mit AI erstellt.

Canopy Growth stock carries a Zacks Rank #4 (Sell) after Zacks Equity Research reported sharp revisions to the company’s earnings outlook on Thursday, November 12, 2026. Zacks said the current fiscal-year consensus estimate had fallen 66.7% over the previous 30 days.

The research firm also cited a 20% reduction in the consensus estimate for the current quarter. Its estimate for the next fiscal year rose 42.9% over the same period, while the current fiscal-year estimate stood at a loss of 0.13 dollars per share. The Zacks Equity Research report said the estimate revisions led to the #4 ranking.

Canopy Growth stock traded at 0.49 euros on Lang & Schwarz at 22:46 CET on Tuesday, November 17, 2026.

Second-quarter growth and continued losses

In its November 6 financial release, Canopy Growth reported consolidated net revenue of C$81.4 million for the three months ended September 30, 2026, up 22% from the prior-year quarter. Cannabis revenue increased 30% to C$66.2 million, while international cannabis revenue rose 141% to C$12.3 million.

The company’s adjusted EBITDA loss narrowed 6% to C$2.9 million. Net loss, however, widened by C$35.7 million, mainly because of C$35.8 million in fair-value charges on Canopy USA-related assets. Free cash outflow declined to C$15.5 million from C$19.2 million a year earlier. The company’s November 6 release attributed the international increase primarily to medical cannabis sales in Germany and Poland.

Canada’s broader market context is covered in current S&P/TSX Composite market reports.

More news and analyses on Canopy Growth stock.

Canopy Growth Corporation

  • ISIN: CA1380357048
  • Tickers: CGC on Nasdaq; WEED on the Toronto Stock Exchange
  • Latest quote: 0.49 euros on Lang & Schwarz, November 17, 2026, 22:46 CET
Disclaimer...
en | CA1380357048 | CGC | boerse | 70528808 | bgmi